IDEAYA Biosciences (IDYA) Prices 6.67M Share Common Offering at $15/Sh

Ideaya Biosciences (IDYA) PT Raised to $22 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $22.00 (from $13.00) while maintaining a Buy rating.... More

IDEAYA Biosciences (IDYA) Announces $60M Proposed Public Offering of Common Stock

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $9 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no... More

Ideaya Biosciences (IDYA) PT Raised to $25 at Oppenheimer

Oppenheimer analyst Kevin DeGeeter raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $25.00 (from $17.00) while maintaining a Outperform rating.

IDEAYA Biosciences (IDYA) Gains 60% on GSK Deal

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) gains 60% as the company GlaxoSmithKline plc (NYSE: GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.

Pre-Open Stock Movers 06/16: (IDYA) (IQ) (HEAR) Higher; (IZEA) (CLDX) (CHK) Lower (more...)

Today'sPre-Open Stock Movers

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) 78.3% HIGHER; IDEAYA and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.

iQIYI (NASDAQ: IQ) 40% HIGHER; Tencent aims to become biggest shareholder of video streaming rival iQIYI - Reuters

Turtle Beach Corporation (NASDAQ: HEAR) 28.7% HIGHER; has increased its sales outlook for the quarter ending June 30, 2020 based on continued strong demand and significant... More

IDEAYA Biosciences (IDYA), GSK (GSK) Announce Broad Partnership in Synthetic Lethality

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.

The strategic partnership includes IDEAYA's Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years. IDEAYA has solved the crystal structures for each of its MAT2A, Pol Theta and Werner Helicase programs, enabling structure-based drug design, and has demonstrated in vivo proof of concept in relevant animal models for its MAT2A and Pol Theta programs.... More